EOSINOPHILIC ESOPHAGITIS

This program provides early access to APT-1011, a swallowed steroid tablet, for people aged 12 and older with eosinophilic esophagitis (EoE) who cannot join other studies or have not responded to available treatments. The goal is to offer a potential treatment option until the dr…

This study tests an investigational drug called tezepelumab in 368 people aged 12 to 80 with eosinophilic esophagitis, a condition that makes swallowing difficult due to allergic inflammation in the esophagus. Participants receive either the drug or a placebo as a shot under the …

This study looks at whether children with eosinophilic esophagitis (a throat condition) can stay well on a lower dose of steroid medicine. About 50 children who are already in remission will be given half their usual steroid dose. The goal is to see if the lower dose still keeps …

This study looks at how well dupilumab, an FDA-approved drug, works for people with severe eosinophilic esophagitis (EoE) and narrowed food pipes. About 23 participants will receive weekly injections for one year. The goal is to reduce inflammation and improve swallowing, with re…

This study tests a special camera capsule that people swallow to take detailed pictures of the esophagus. It includes healthy volunteers and people with eosinophilic esophagitis (EoE). The goal is to see if the capsule works well and is comfortable enough to use in the future.

This study aimed to see if a special camera inside a pill-sized capsule could diagnose eosinophilic esophagitis and Barrett esophagus as well as standard biopsy. It planned to include healthy adults and teens being checked for these conditions. However, the study was withdrawn be…

This study is looking at the biological and genetic reasons why some people develop food allergies and others outgrow them. Researchers will collect blood samples from up to 5,300 people, including those with food allergies, their family members, and healthy volunteers. The goal …

This study planned to check if swallowed corticosteroids, a common treatment for eosinophilic esophagitis (EoE) in children, could harm bone density or slow growth. It was designed for kids aged 5-12 with EoE who were starting this medication. However, the study was withdrawn bef…